https://wikimd.org/index.php?action=history&feed=atom&title=SiponimodSiponimod - Revision history2026-04-26T04:22:05ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=Siponimod&diff=2393362&oldid=prevPrab at 12:48, 14 July 20212021-07-14T12:48:34Z<p></p>
<p><b>New page</b></p><div>=='''What is {{PAGENAME}}?'''==<br />
US FDA approved under the brandname Mayzent, Siponimod is a sphingosine 1-phosphate (s1p) receptor modulator indicated for the treatment of relapsing forms of [[multiple sclerosis]] (ms)<br />
[[File:Siponimod.svg|alt=Siponimod structure|thumb|'''Siponimod structure''']]<br />
<youtube><br />
title='''{{PAGENAME}}'''<br />
movie_url=http://www.youtube.com/v/etQFE36veRs<br />
embed_source_url=http://www.youtube.com/v/etQFE36veRs<br />
wrap = yes<br />
width=750<br />
height=600<br />
</youtube> <br />
=='''What are the uses of {{PAGENAME}}?'''==<br />
Mayzent is a sphingosine 1-phosphate (s1p) receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. <br />
<br />
=='''How does {{PAGENAME}} work?'''==<br />
* Siponimod is an S1P receptor modulator. <br />
* Siponimod binds with high affinity to S1P receptors 1 and 5. <br />
* Siponimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of [[lymphocytes]] in peripheral blood. <br />
* The exact mechanism by which siponimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.<br />
<br />
=='''Who Should Not Use {{PAGENAME}}?'''==<br />
* Patients with a CYP2C93/3 genotype. <br />
* In the last 6 months, experienced [[myocardial infarction]], [[unstable angina]], [[stroke]], [[TIA]], decompensated heart failure requiring hospitalization, or class III/IV [[heart failure]]. <br />
* Presence of [[Mobitz type II]] second-degree, [[heart block|third-degree AV block]], or [[sick sinus syndrome]], unless patient has a functioning [[pacemaker]]. <br />
* Warnings and precautions<br />
* '''Infections:''' mayzent may increase the risk. Obtain a [[complete blood count]] (cbc) before initiating treatment. Monitor for infection during treatment. Do not start in patients with active infection. <br />
* '''Macular edema:''' an ophthalmic evaluation is recommended before starting treatment and if there is any change in vision while taking mayzent. Diabetes mellitus and uveitis increase the risk. <br />
* '''Bradyarrhythmia''' and atrioventricular conduction delays: mayzent may result in a transient decrease in heart rate; titration is required for treatment initiation. Consider resting heart rate with concomitant beta-blocker use; obtain cardiologist consultation before concomitant use with other drugs that decrease heart rate. <br />
* '''Respiratory effects:''' may cause a decline in pulmonary function. Assess pulmonary function (e.G., spirometry) if clinically indicated. <br />
* '''Liver injury:''' obtain liver enzyme results before initiation. Closely monitor patients with severe hepatic impairment. Discontinue if significant liver injury occurs. <br />
* '''Cutaneous malignancies:''' periodic skin examination is recommended. <br />
* '''Increased blood pressure:''' monitor blood pressure (bp) during treatment. <br />
* '''Fetal risk:''' women of childbearing potential should use effective contraception during and for 10 days after stopping mayzent. <br />
<br />
=='''Is {{PAGENAME}} FDA approved?'''==<br />
Yes. It is US FDA approved under the brandname Mayzent in March of 2019.<br />
<br />
=='''How should {{PAGENAME}} be used?'''==<br />
* Assessments are required prior to initiating mayzent. <br />
* Titration is required for treatment initiation. <br />
* The recommended maintenance dosage is 2 mg. <br />
* The recommended maintenance dosage in patients with a cyp2c9*1/*3 or *2/*3 genotype is 1 mg. <br />
* Administer tablets whole; do not split, crush, or chew.<br />
* First-dose monitoring is recommended for patients with sinus bradycardia, first- or second-degree [mobitz type I] atrioventricular (av) block, or a history of myocardial infarction or heart failure. <br />
<br />
=='''What are the dosage forms and brand names of {{PAGENAME}}?'''==<br />
It comes as tablets of 0.25 mg and 2 mg<br />
<br />
=='''What side effects can {{PAGENAME}} cause?'''==<br />
Most common adverse reactions (incidence greater than 10%) are headache, hypertension, and transaminase increases. <br />
<br />
==''' What special precautions should I follow?'''==<br />
* Vaccination: avoid live attenuated vaccines during and for up to 4 weeks after treatment with mayzent. <br />
* Cyp2c9 and cyp3a4 inhibitors: increase in siponimod exposure; concomitant use of mayzent with moderate cyp2c9 and moderate or strong cyp3a4 inhibitors is not recommended.<br />
* Cyp2c9 and cyp3a4 inducers: decrease in siponimod exposure; concomitant use of mayzent with moderate cyp2c9 and strong cyp3a4 inducers is not recommended<br />
<br />
=='''What to do in case of emergency/overdose?'''==<br />
* {{overdose}}<br />
<br />
=='''Can {{PAGENAME}} be used in pregnancy?'''==<br />
No<br />
<br />
=='''Can {{PAGENAME}} be used in children?'''==<br />
Not studied in children<br />
<br />
=='''What are the active and inactive ingredients in {{PAGENAME}}?==<br />
'''Active ingredients'''<br />
* Siponimod<br />
<br />
'''Inactive ingredients'''<br />
* Lactose monohydrate <br />
* Cellulose, microcrystalline <br />
* Crospovidone, unspecified <br />
* Glyceryl dibehenate <br />
* Silicon dioxide<br />
* Talc <br />
* Titanium dioxide<br />
* Ferric oxide red<br />
* Ferric oxide yellow<br />
<br />
=='''What should I know about storage and disposal of {{PAGENAME}}?'''==<br />
'''Unopened Containers'''<br />
* MAYZENT 0.25 mg and 2 mg tablets may be stored at room temperature between 68°F to 77°F (20°C to 25°C) for up to 3 months. If you need to store MAYZENT tablets for more than 3 months, containers should remain unopened and stored in a refrigerator between 36°F to 46°F (2°C to 8°C) until use.<br />
<br />
'''Opened Containers'''<br />
<br />
''Bottles''<br />
<br />
* MAYZENT 0.25 mg and 2 mg tablets may be stored at room temperature between 68°F to 77°F (20°C to 25°C) for up to 3 months. <br />
* Do not refrigerate after opening.<br />
<br />
''Starter Pack/Blister Card''<br />
<br />
* MAYZENT 0.25 mg tablets may be stored at room temperature between 68°F to 77°F (20°C to 25°C) for up to 3 months. <br />
* Do not refrigerate after opening. <br />
* Store in original calendarized blister wallet container.<br />
* Keep MAYZENT and all medicines out of the reach of children.<br />
<br />
=='''Who manufactures and distributes {{PAGENAME}}?'''==<br />
* [[Novartis]]<br />
<br />
{{coststubd}}<br />
{{Demyelinating diseases of CNS}}<br />
{{Immunosuppressants}}<br />
{{Sphingolipids}}<br />
{{Lysophospholipid signaling}}<br />
{{Portal bar | Medicine}}<br />
[[Category:Azetidines]]<br />
[[Category:Lipids]]<br />
[[Category:Multiple sclerosis]]<br />
[[Category:Novartis brands]]<br />
[[Category:Trifluoromethyl compounds]]</div>Prab